A detailed history of Schonfeld Strategic Advisors LLC transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 31,022 shares of AGIO stock, worth $1.83 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
31,022
Previous 464,121 93.32%
Holding current value
$1.83 Million
Previous $20 Million 93.11%
% of portfolio
0.01%
Previous 0.14%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$41.19 - $49.72 $17.8 Million - $21.5 Million
-433,099 Reduced 93.32%
31,022 $1.38 Million
Q2 2024

Aug 14, 2024

BUY
$27.55 - $48.83 $12.8 Million - $22.7 Million
464,121 New
464,121 $20 Million
Q4 2022

Feb 14, 2023

BUY
$24.81 - $31.52 $587,997 - $747,024
23,700 New
23,700 $665,000
Q1 2022

May 16, 2022

SELL
$26.68 - $34.81 $301,484 - $393,353
-11,300 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$29.58 - $49.78 $334,254 - $562,514
11,300 New
11,300 $371,000
Q3 2021

Nov 16, 2021

SELL
$41.92 - $58.18 $923,707 - $1.28 Million
-22,035 Closed
0 $0
Q2 2021

Nov 16, 2021

SELL
$52.06 - $61.27 $734,046 - $863,907
-14,100 Reduced 39.02%
22,035 $1.21 Million
Q2 2021

Aug 16, 2021

BUY
$52.06 - $61.27 $437,251 - $514,606
8,399 Added 30.28%
36,135 $1.99 Million
Q1 2021

May 17, 2021

BUY
$44.23 - $57.5 $1.23 Million - $1.59 Million
27,736 New
27,736 $1.43 Million
Q4 2020

Feb 16, 2021

SELL
$33.21 - $46.54 $744,833 - $1.04 Million
-22,428 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$33.87 - $55.93 $545,103 - $900,137
16,094 Added 254.09%
22,428 $1,000
Q2 2020

Aug 14, 2020

SELL
$34.45 - $53.48 $4,616 - $7,166
-134 Reduced 2.07%
6,334 $339,000
Q1 2020

May 15, 2020

BUY
$31.52 - $53.81 $203,871 - $348,043
6,468 New
6,468 $229,000

Others Institutions Holding AGIO

About AGIOS PHARMACEUTICALS, INC.


  • Ticker AGIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,818,000
  • Market Cap $3.24B
  • Description
  • Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...
More about AGIO
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.